companydata.dkcompanydata.dk

Y-mAbs Therapeutics A/S: Financial statements 2023

CVR: 37053678

Source: annual report 2023, Danish Business Authority

01/01/2023 – 31/12/2023

Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 70,656,043 and a net result of DKK -27,748,840 compared with DKK -85,685,825 the year before. That is a decrease of 14.2% compared with the year before. Equity in the 2023 report amounted to DKK -112,689,781. The company had 59 employees in the financial year.

Gross Profit
DKK 70,656,043
Profit/Loss
DKK -27,748,840
Equity
DKK -112,689,781
Total Assets
DKK 56,658,376
Employees
59

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023-70.7M-27.7M-112.7M59
2022-82.3M-85.7M-84.9M101
2021-67.5M-42.1M-39.3M88
2020-82.4M-1.2M2.8M62
2019-52M-2.6M4M36

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Michael Joseph Rossi joins the board of Y-mAbs Therapeutics A/SNov 29, 2023

As of November 29, 2023, Michael Joseph Rossi has joined the board of directors of Y-mAbs Therapeutics A/S.

Michael Joseph Rossi joins Y-mAbs Therapeutics A/S as adm. dir.Nov 28, 2023

As of November 28, 2023, Michael Joseph Rossi is registered as adm. dir. of Y-mAbs Therapeutics A/S.

Thomas Gad steps down as adm. dir. of Y-mAbs Therapeutics A/SNov 28, 2023

As of November 28, 2023, Thomas Gad has stepped down as adm. dir. of Y-mAbs Therapeutics A/S.

Y-mAbs Therapeutics A/S: The 2022 annual report is outJul 10, 2023

Y-mAbs Therapeutics A/S has published its annual report for 2022. Gross profit came to DKK 82,332,358, and the net result was DKK -85,685,825.

About Y-mAbs Therapeutics A/S

Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.

Source: annual report 2025, Danish Business Authority